If you or a loved one has been on Tysabri for multiple sclerosis, you may have heard about the risk of progressive multifocal leukoencephalopathy (PML). The relationship between cumulative dose, duration of therapy, and PML incidence is a critical area of ongoing research. Building on decades of pharmacovigilance data, this page provides a focused overview of what New York patients should know about PML risk in the context of Tysabri treatment.
Tysabri (natalizumab) is a biologic therapy approved for the treatment of multiple sclerosis and Crohn's disease. Its use carries a well-documented risk of Progressive Multifocal Leukoencephalopathy (PML), a severe and often fatal brain infection. This section reviews the clinical presentation of PML, the pharmacological link to Tysabri, and the risk considerations for affected patients, including legal implications. Progressive Multifocal Leukoencephalopathy is a demyelinating disease of the central nervous system caused by the JC polyomavirus (JCV). It typically occurs in individuals with compromised immune systems. The clinical presentation can vary, but common symptoms include progressive neurological deficits such as weakness, sensory loss, cognitive decline, visual disturbances, and speech difficulties. Diagnosis is confirmed through a combination of clinical evaluation, brain imaging (typically MRI showing multifocal white matter lesions), and detection of JCV DNA in cerebrospinal fluid or brain biopsy. A retrospective national cohort study of 456 PML cases observed between 1987 and 2024 described the demographic, clinical, radiological, and laboratory characteristics of the disease, noting that survival and presentation can vary based on the underlying condition (https://pubmed.ncbi.nlm.nih.gov/40922664/). Early recognition is critical, as PML usually leads to death or severe disability if not promptly managed.
Tysabri is a monoclonal antibody that binds to alpha-4 integrins on the surface of immune cells, preventing their migration into the central nervous system. This mechanism reduces inflammation in multiple sclerosis but also impairs immune surveillance, particularly against the JC virus. The drug's prescribing information includes a boxed warning stating that Tysabri increases the risk of PML, an opportunistic viral infection of the brain that usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). In clinical trials, PML occurred in three patients: two among 1869 multiple sclerosis patients treated for a median of 120 weeks (who also received interferon beta-1a), and one among 1043 Crohn's disease patients after eight doses (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Other adverse reactions include headache, influenza-like illness, peripheral edema, and infections such as influenza and sinusitis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
The primary mechanism linking Tysabri to PML involves reduced immune surveillance in the brain. By blocking lymphocyte trafficking, Tysabri diminishes the ability of the immune system to control JCV replication. The drug's label identifies three key risk factors for PML: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered when initiating and continuing therapy. The label also mandates that Tysabri be withheld immediately at the first sign or symptom suggestive of PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Because of the PML risk, Tysabri is only available through a restricted distribution program called the TOUCH Prescribing Program (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
The prescribing information for Tysabri includes a prominent boxed warning that clearly states the increased risk of PML and the factors that elevate that risk. The warning advises healthcare professionals to monitor patients for any new signs or symptoms suggestive of PML and to withhold dosing immediately if such symptoms appear (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). While these warnings are explicit, questions may arise about whether patients and providers fully understand the magnitude of risk, especially given the potential for delayed onset or atypical presentations. The label also notes that PML typically occurs only in immunocompromised patients, but Tysabri itself induces a state of relative immunosuppression in the brain (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). For patients who develop PML after Tysabri treatment, legal considerations may include whether the warnings provided were adequate and whether the risk was properly communicated. The boxed warning and restricted distribution program demonstrate that the manufacturer recognized the risk, but individual cases may involve questions about informed consent, monitoring practices, or failure to promptly withhold treatment. Patients or their families may seek legal counsel to explore claims related to product liability or medical negligence. The timeline between exposure and documented harm is critical: PML can occur after varying durations of treatment, with risk increasing beyond two years (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). In clinical trials, cases were observed after 8 doses (Crohn's disease) and after a median of 120 weeks (multiple sclerosis) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This variability underscores the need for careful documentation of treatment duration and any symptoms.
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Tysabri (natalizumab) is a biologic therapy for multiple sclerosis and Crohn's disease. It increases the risk of Progressive Multifocal Leukoencephalopathy (PML), a severe brain infection caused by the JC virus, due to reduced immune surveillance in the brain. The drug's label includes a boxed warning about this risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
Symptoms include progressive neurological deficits such as weakness, sensory loss, cognitive decline, visual disturbances, and speech difficulties. Diagnosis is confirmed via MRI showing white matter lesions and detection of JCV DNA in cerebrospinal fluid or brain biopsy (https://pubmed.ncbi.nlm.nih.gov/40922664/).
Patients may pursue product liability or medical negligence claims, focusing on inadequate warnings, failure to monitor, or delayed treatment. An experienced attorney can evaluate the case based on treatment duration, risk factors, and documentation (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.
Individuals with documented Tysabri exposure and a related diagnosis may request an independent, no-cost eligibility review.
Request archival records or inquire about member-exclusive transition and benefit programs.